Aerogen technology reduces Emergency Department admissions by 32% when compared to a standard jet nebulizer

This large clinical study demonstrates the impact Aerogen technology can have in the Emergency Department

Data recently released reinforced Aerogen's credentials as global leaders in high performance aerosol drug delivery. The results from this study showed a 32% reduction in the admission of patients to hospital from the emergency department when treated with their vibrating mesh technology compared to traditional jet nebulisers.

The same research also showed that patients treated with Aerogen technology in the same setting required 75% less medication versus those treated with traditional small volume jet nebulisers. Secondary analysis also confirmed a significant reduction in median length of stay of 37 minutes.

Commenting on the results, John Power, Managing Director and CEO of Aerogen said, “This large clinical study demonstrates the impact Aerogen technology can have in the Emergency Department and is further evidence of the outstanding clinical results we’ve seen when Aerogen technology is used in critical care units all over the world, “.

“When patients feel better and can go home faster, without an extended hospital stay, it benefits everyone. This is truly great news for patients, clinicians and hospital administrators alike.”

Lead investigator and study author Robert Dunne, MD, Vice Chair of Emergency Medicine at St. John Medical Centre, Detroit said “The study results prove what we saw everyday treating patients in our emergency room: people who needed treatment with a bronchodilator got better faster, with less medicine, and required fewer admissions when using the Aerogen Solo and Ultra than patients receiving treatment with a traditional small volume jet nebuliser,”

Dunne R et al. Aerosol dose matters in the Emergency Department: A comparison of impact of bronchodilator administration with two nebulizer systems. Poster at the American Association for Respiratory Care. 2016